Table 3 Respiratory support for subjects intubated early (< 15 min from birth) compared with subjects managed initially with non-invasive respiratory support and/or intubated ≥15 min from birth
Intubated < 15 min of Birth | Not intubated < 15 min of Birth | |||||||
|---|---|---|---|---|---|---|---|---|
26–28 + 6 weeks | 29–32 + 6 weeks | 33–34 + 6 weeks | Overall (N = 310) | 26–28 + 6 weeks | 29–32 + 6 weeks | 33–34 + 6 weeks | Overall (N = 1783) | |
(N = 157) | (N = 111) | (N = 42) | (N = 221) | (N = 724) | (N = 838) | |||
Diagnosed with RDS, n (%) | 107 (68%) | 62 (56%) | 18 (43%) | 187 (60%) | 100 (45%) | 268 (37%) | 177 (21%) | 545 (31%) |
Surfactant, n (%) | 142 (90%) | 90 (81%) | 21 (50%) | 253 (82%) | 118 (53%) | 170 (23%) | 83 (10%) | 371 (21%) |
Standard approach | 135 (95%) | 82 (91%) | 20 (95%) | 237 (94%) | 87 (74%) | 105 (62%) | 57 (69%) | 249 (67%) |
INSURE | 5 (3%) | 2 (2%) | 0 | 7 (3%) | 22 (19%) | 53 (31%) | 19 (23%) | 94 (25%) |
LISA | 0 | 0 | 0 | 0 | 6 (5%) | 8 (5%) | 1 (1%) | 15 (4%) |
Not available, n (%) | 2 (1%) | 6 (7%) | 1 (5%) | 9 (4%) | 3 (3%) | 4 (2%) | 6 (7%) | 13 (4%) |
Methylxanthines, n (%) | 153 (98%) | 99 (89%) | 9 (21%) | 261 (84%) | 216 (98%) | 509 (70%) | 133 (16%) | 858 (48%) |
Caffeine, n (%) | 147 (96%) | 94 (95%) | 8 (89%) | 249 (95%) | 174 (81%) | 439 (86%) | 123 (92%) | 736 (86%) |
Aminophylline, n (%) | 5 (4%) | 5 (5%) | 1 (11%) | 11 (5%) | 42 (19%) | 68 (13%) | 9 (7%) | 119 (14%) |
Not Available, n (%) | 1 (< 1%) | 0 | 0 | 1 (< 1%) | 0 | 2 (< 1%) | 1 (1%) | 3 (< 1%) |
Started on CPAP, n (%) | 8 (5%) | 5 (5%) | 1 (2%) | 14 (5%) | 139 (63%) | 429 (59%) | 307 (37%) | 875 (49%) |
CPAP Failure, n (%) | 8 (100%) | 5 (100%) | 1 (100%) | 14 (100%) | 67 (48%) | 109 (25%) | 61 (20%) | 237 (27%) |
Endotracheal Intubation, n (%) | 157 (100%) | 111 (100%) | 42 (100%) | 310 (100%) | 138 (62%) | 165 (23%) | 95 (11%) | 398 (22%) |